IP Library Granted Patent US 8,298,817
Granted Patent B2
US 8,298,817 · App. 11/252,063 · Granted Oct 30, 2012

Vector

Assignees: National Cerebral and Cardiovascular Center; Bridgestone Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,298,817
App. No.
11/252,063
Granted
Oct 30, 2012
Kind
B2
Abstract

The present invention provides a vector which can make nucleic acids to be an aggregate and locate a vector containing a cationic polymer to surround the aggregate so as to protect the nucleic acids from the enzyme. The vector comprises a polymer having branched chain(s). Preferably, 3, 4, or 6 branched chains are bonded to benzene ring. It is preferable that the number of the branched chains is higher. As the branched chain(s), a vinyl-series acrylic polymer is preferable. The vector is synthesized by reacting a dithiocarbamate compound with an acrylamide monomer for the branched chain(s).

Claims (11)

1. A nucleic-acid-containing complex comprising a nucleic acid and a vector, wherein the vector is represented by a Formula selected from the group consisting of Formula (I) and Formula (II):

wherein R 1 -R 6 each represent polymer chains, wherein R 1 -R 6 may each be the same or different,

wherein R 7 -R 10 each represent polymer chains, wherein R 7 -R 10 may each be the same or different,

wherein the polymer chains represented by R 1 -R 10 are polymers consisting of dimethylaminopropyl acrylamide monomers, and

wherein said nucleic-acid-containing complex has a particle size of about 50 to about 400 nm.

2. The nucleic-acid-containing complex of claim 1 , wherein the vector is of Formula II and has a molecular weight of from 30,000 to 65,000.

3. The nucleic-acid-containing complex of claim 1 , wherein the vector is of Formula I and has a molecular weight of from 10,000 to 50,000.

4. A nucleic-acid-containing complex as claimed in claim 1 , wherein said vector is represented by Formula (I).

5. The nucleic-acid-containing complex of claim 1 , wherein the molecular weight of the vector is from 5,000 to 500,000.

6. The nucleic-acid-containing complex of claim 1 , wherein the molecular weight of the vector is from 5,000 to 50,000.

7. The nucleic-acid-containing complex as claimed in claim 1 , wherein said nucleic-acid-containing complex has a particle size of approximately 250 nm, wherein a cation/anion ratio of said nucleic-acid-containing complex is 20 to 160, and wherein the vector is represented by Formula (I) and has a molecular weight of approximately 18,000.

Assignments (2)
CHANGE OF NAME Recorded Oct 15, 2010
From: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CARDIOVASCULAR CENTER
To: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
Reel/Frame 025143/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2005
From: NAKAYAMA, YASUHIDE; NAGAISHI, MAKOTO; SHIBA, MARIKO
To: JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CARDIOVASCULAR CENTER; BRIDGESTONE CORPORATION
Reel/Frame 017111/0677 →
Priority Claims (1)
JP 2003-114541 · Apr 18, 2003 · national
Continuity (2)
Continuation PCTJP2004005450 · Apr 16, 2004
Related Publication 20060057714A1 · Mar 16, 2006